Daily Endocrinology Research Analysis
Analyzed 42 papers and selected 3 impactful papers.
Summary
Analyzed 42 papers and selected 3 impactful articles.
Selected Articles
1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
In a prespecified subgroup of 3655 high-risk patients with diabetes and no known significant atherosclerosis, evolocumab added to statins reduced first MACE (HR 0.69 for both 3- and 4-point composites) over a median 4.8 years, with LDL-C lowered to 52 mg/dL at 48 weeks. All-cause mortality was numerically lower (HR 0.76). These data support extending PCSK9 inhibition to primary prevention in selected high-risk diabetic patients.
Impact: This robust RCT subgroup analysis demonstrates primary prevention benefit of PCSK9 inhibition in high-risk diabetic patients without known atherosclerosis, potentially shifting preventive lipid-lowering strategies.
Clinical Implications: Consider evolocumab for primary prevention in high-risk patients with diabetes whose LDL-C remains elevated despite statins, balancing absolute risk reductions (~2–3% over 5 years) against cost and injection burden.
Key Findings
- In 3655 diabetic patients without known significant atherosclerosis, evolocumab reduced 3-point MACE (HR 0.69; 95% CI 0.52–0.91).
- Evolocumab reduced 4-point MACE (HR 0.69; 95% CI 0.55–0.86) with an absolute 5-year difference of 2.9%.
- LDL-C at 48 weeks was 52 mg/dL with evolocumab vs 111 mg/dL with placebo on top of statins.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with prespecified subgroup
- Large sample size and long median follow-up (4.8 years) with clear lipid separation
Limitations
- Subgroup analysis limits generalizability beyond patients without known atherosclerosis
- Cost, access, and detailed adverse event profiles are not delineated in the abstract
Future Directions: Head-to-head comparisons against other nonstatin therapies and cost-effectiveness analyses in primary prevention for diabetes; assessment of long-term safety and subpopulation benefits.
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis. OBJECTIVE: To investigate whether evolocumab could prevent a first major cardiovascular event (MACE) in patients without known significant atherosclerosis. DESIGN, SETTING, AND PARTICIPANTS: VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab conducted across 774 sites in 33 countries and enrolling 12 257 patients with no prior myocardial infarction or stroke, LDL-C level 90 mg/dL or greater, and qualifying atherosclerosis or high-risk diabetes. This prespecified subgroup analysis examined outcomes in patients without known significant atherosclerosis (none of the following: prior arterial revascularization, arterial stenosis ≥50%, or coronary artery calcium score ≥100 Agatston units), all of whom had diabetes. Enrollment started in June 2019 and the last patient visit was July 2025, with a median follow-up of 4.8 years. INTERVENTION: Patients were randomized in a 1:1 ratio to subcutaneous administration of either evolocumab (140 mg every 2 weeks) or matching placebo added to optimally tolerated statin therapy. MAIN OUTCOMES AND MEASURES: The dual primary end points were composites of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE) and 3-P MACE plus ischemia-driven arterial revascularization (4-P MACE). Secondary end points included all-cause mortality. RESULTS: This predefined subgroup included 3655 patients (1849 in the evolocumab group and 1806 in the placebo group) with a median age of 65 years (57% female). Among those in the lipid substudy, the median LDL-C level at 48 weeks was 52 mg/dL in the evolocumab group vs 111 mg/dL in the placebo group (P < .001). A 3-P MACE event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group compared with 117 patients (5-year Kaplan-Meier estimate, 7.1%) in the placebo group (hazard ratio [HR], 0.69 [95% CI, 0.52-0.91]; P = .009; between-group difference, 2.1% [95% CI, 0.4%-3.8%]). A 4-P MACE event occurred in 127 patients (5-year Kaplan-Meier estimate, 7.6%) in the evolocumab group compared with 178 patients (5-year Kaplan-Meier estimate, 10.5%) in the placebo group (HR, 0.69 [95% CI, 0.55-0.86]; P = .001; between-group difference, 2.9% [95% CI, 0.9%-4.9%]). There were 136 deaths (5-year Kaplan-Meier estimate, 7.8%) in the evolocumab group compared with 172 deaths (5-year Kaplan-Meier estimate, 10.1%) in the placebo group (HR, 0.76 [95% CI, 0.61-0.95]). CONCLUSIONS AND RELEVANCE: In high-risk patients without known significant atherosclerosis and with diabetes, evolocumab reduced the risk of a first major cardiovascular event. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03872401.
2. Maltol induces diabetic fragility fractures by disrupting the balance of bone remodeling.
Using human tissue metabolomics with in vivo and in vitro validation, the study identifies maltol as a diet-derived factor that worsens diabetic skeletal fragility by suppressing osteoblastogenesis (via Wnt/β-catenin) and enhancing osteoclastogenesis (via NF-κB). Hyperglycemia amplifies these effects, whereas insulin normalization blunts maltol-induced skeletal damage in mice, suggesting the need for metabolic context-aware additive safety and dietary guidance.
Impact: This work uncovers a modifiable, diet-derived factor driving diabetic skeletal fragility with clear mechanistic underpinnings, bridging clinical metabolomics and causal pathways to inform public health and clinical nutrition in diabetes.
Clinical Implications: Dietary counseling for patients with diabetes may consider reducing exposure to maltol-rich processed foods; regulators may need to assess additive safety under hyperglycemic conditions. Therapies targeting Wnt/β-catenin or NF-κB pathways could mitigate risk.
Key Findings
- Maltol accumulated in femoral neck tissue of diabetic individuals with fragility fractures, and higher circulating maltol correlated with increased fracture incidence.
- Maltol suppressed osteoblast differentiation via Wnt/β-catenin and promoted osteoclast maturation via NF-κB, disrupting bone remodeling.
- Hyperglycemia amplified maltol’s deleterious effects, while insulin normalization mitigated skeletal deterioration in mouse models.
Methodological Strengths
- Integrated clinical metabolomics with in vivo and in vitro validation across multiple systems
- Mechanistic pathway dissection (Wnt/β-catenin and NF-κB) with functional rescue by insulin in animal models
Limitations
- Human exposure quantification and prospective causal validation are limited
- Generalizability across diverse diets and diabetes phenotypes requires further study
Future Directions: Prospective cohort and interventional dietary studies quantifying maltol exposure; evaluation of regulatory thresholds under hyperglycemia; testing pathway-targeted therapies to prevent fractures in diabetes.
Type 2 diabetes is a major risk factor for fragility fractures, yet the contributors to skeletal fragility remain unclear. Through integrated clinical metabolomics, in vivo, and in vitro analyses, we identify maltol-a widely used food additive-as a previously unrecognized risk factor for hyperglycemia-associated bone fragility. Metabolomic profiling of femoral neck tissue from individuals with fragility fractures showed diabetes-associated maltol accumulation, and elevated circulating maltol levels correlated with increased fracture incidence. Mechanistically, maltol inhibits osteoblast differentiation via Wnt/β-catenin and promotes osteoclast maturation through nuclear factor κB (NF-κB) signaling, disrupting bone remodeling. These effects are amplified under hyperglycemia, while insulin reversal of glucose levels mitigates maltol-induced skeletal deterioration in mouse models. Given the widespread use of maltol in processed foods, these findings suggest that food additive safety should consider metabolic context and call for disease-specific dietary exposure guidelines to reduce fracture risk in diabetes.
3. Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: A comprehensive updated systematic review and meta-analysis.
Across 22 studies including 1324 adults with type 1 diabetes, metabolic/bariatric surgery produced substantial weight loss (mean −29.6 kg) and reduced insulin requirements, with only minimal HbA1c improvement. Given heterogeneous methods and inconsistent safety reporting, the true metabolic risk profile remains uncertain, underscoring the need for standardized prospective studies.
Impact: This synthesis clarifies realistic expectations of metabolic/bariatric surgery in type 1 diabetes—robust weight loss and insulin-sparing effects without major HbA1c gains—guiding patient selection and counseling.
Clinical Implications: For adults with type 1 diabetes and obesity, counsel that MBS can reduce insulin needs and weight but may not markedly improve HbA1c; ensure standardized safety monitoring and multidisciplinary follow-up.
Key Findings
- Meta-analysis of 22 studies (n=1324) showed significant weight loss after MBS (mean difference −29.55 kg; 95% CI −33.39 to −25.72).
- Insulin requirements decreased postoperatively, while HbA1c improvements were minimal.
- Most procedures were Roux-en-Y gastric bypass (44.5%) and sleeve gastrectomy (39.2%); safety reporting was inconsistent.
Methodological Strengths
- PRISMA-compliant, PROSPERO-registered review with ROBINS-I/RoB-2 bias assessment and GRADE certainty grading
- Large aggregated sample with broad procedural representation (RYGB, sleeve gastrectomy)
Limitations
- Predominantly observational evidence with heterogeneity and incomplete adverse event reporting
- Potential selection bias and lack of standardized outcome definitions across studies
Future Directions: High-quality prospective, ideally randomized, studies with standardized safety and metabolic outcome definitions to define risk-benefit and subpopulation responses in type 1 diabetes.
AIMS: This systematic review evaluated the impact of metabolic and bariatric surgery (MBS) on weight loss, glycaemic control, insulin requirements and postoperative complications. METHODS: A PRISMA-compliant, PROSPERO-registered systematic review and meta-analysis (CRD42025123500) was conducted. Medline, PubMed, Embase, Scopus and CENTRAL were searched. Primary outcomes were changes in body weight, BMI, HbA1c and insulin requirements following MBS. Risk of bias was assessed using ROBINS-I and RoB-2, and certainty of evidence using GRADE. RESULTS: Twenty-two studies, including 1324 adults with type 1 diabetes mellitus (mean age 42.2 ± 11.6 years; mean follow-up 31.6 ± 18.2 months), were analysed. Of 753 participants with reported sex, 74.6% were women (n = 562). A total of 1304 procedures were performed, most commonly Roux-en-Y gastric bypass (44.5%; n = 580) and sleeve gastrectomy (39.2%; n = 512), followed by adjustable gastric banding (13.0%; n = 170). Meta-analysis demonstrated significant reductions in body weight (mean difference 29.55 kg; 95% CI 25.72 to 33.39; I CONCLUSION: MBS achieves weight loss and reduces insulin requirements in adults with type 1 diabetes mellitus and obesity, but glycaemic improvements are minimal. Given the observational evidence base and inconsistent safety reporting, true metabolic risk remains uncertain. High-quality prospective studies with standardised outcome definitions are needed.